MX2009006215A - 4-imidazolinas como ligandos de aminas trazas. - Google Patents
4-imidazolinas como ligandos de aminas trazas.Info
- Publication number
- MX2009006215A MX2009006215A MX2009006215A MX2009006215A MX2009006215A MX 2009006215 A MX2009006215 A MX 2009006215A MX 2009006215 A MX2009006215 A MX 2009006215A MX 2009006215 A MX2009006215 A MX 2009006215A MX 2009006215 A MX2009006215 A MX 2009006215A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- sup
- lower alkyl
- phenyl
- lower alkoxy
- Prior art date
Links
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical class C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 102000011829 Trace amine associated receptor Human genes 0.000 abstract 2
- 108050002178 Trace amine associated receptor Proteins 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- -1 hydroxy, amino Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 101000890887 Homo sapiens Trace amine-associated receptor 1 Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 102100040114 Trace amine-associated receptor 1 Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 230000036760 body temperature Effects 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 238000005265 energy consumption Methods 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000007958 sleep Effects 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a compuestos de la fórmula (ver fórmula (I)) en la que R es hidrógeno, alquilo inferior o amino; X-R1 es -CH2-, -CH(alcoxi inferior)- o -CH(OH)- y Y-R2 es -CH2-, -CH(alquilo inferior)-, -CH(alcoxi inferior)- -O-, -S-, -S(O)-, S(O)2-, -CH(fenil)- o -C(alquilo inferior)2-; o X-R1 es -NH- y Y-R2 es -CH2, -CH(alquilo inferior)-, -CH(alcoxi inferior)-, -CH(fenil)- o -C(alquilo inferior)2-; es fenilo, naftilo o benzofuranilo, los anillos están sin sustituir o sustituidos por uno o más sustituyentes elegidos entre el grupo formado por alquilo inferior, alquilo inferior sustituido por halógeno, halógeno, alcoxi inferior, alcoxi inferior sustituido por halógeno, hidroxi, amino, di-alquilamino, morfolinilo, fenilo, bencilo y por O-bencilo; o las sales de adición de ácido farmacéuticamente aceptables. Se ha encontrado que los compuestos de la fórmula I tienen buena afinidad con los receptores asociados con las aminas trazas (TAAR), en especial con el TAAR1. Los compuestos pueden utilizarse para el tratamiento de la depresión, los trastornos de ansiedad, el trastorno bipolar, el trastorno de hiperactividad con déficit de atención (ADHD), los trastornos relacionados con el estrés, los trastornos psicóticos como la esquizofrenia, las enfermedades neurológicas como es la enfermedad de Parkinson, los trastornos neurodegenerativos como es la enfermedad de Alzheimer, la epilepsia, la migraña, la hipertensión, el abuso de sustancias y lo trastornos metabólicos como son los trastornos de ingestión de comida, la diabetes, las complicaciones diabéticas, la obesidad, la dislipidemia, los trastornos de consumo y asimilación de energía, los trastornos y la difusión de la temperatura corporal, la homeostasis, los trastornos del sueño y del ritmo circadiano y los trastornos cardiovasculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06126307 | 2006-12-18 | ||
| PCT/EP2007/063585 WO2008074679A2 (en) | 2006-12-18 | 2007-12-10 | 4-imidazolines as taar's ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006215A true MX2009006215A (es) | 2009-06-22 |
Family
ID=39153757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006215A MX2009006215A (es) | 2006-12-18 | 2007-12-10 | 4-imidazolinas como ligandos de aminas trazas. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20080146523A1 (es) |
| EP (1) | EP2094668A2 (es) |
| JP (1) | JP5175297B2 (es) |
| KR (1) | KR101188992B1 (es) |
| CN (1) | CN101578271B (es) |
| AR (1) | AR064376A1 (es) |
| AU (1) | AU2007336351A1 (es) |
| BR (1) | BRPI0721291A2 (es) |
| CA (1) | CA2671838A1 (es) |
| CL (1) | CL2007003653A1 (es) |
| IL (1) | IL198878A0 (es) |
| MX (1) | MX2009006215A (es) |
| NO (1) | NO20091936L (es) |
| PE (1) | PE20081386A1 (es) |
| RU (1) | RU2465269C2 (es) |
| TW (1) | TWI345467B (es) |
| WO (1) | WO2008074679A2 (es) |
| ZA (1) | ZA200903841B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2121641B1 (en) | 2007-02-15 | 2014-09-24 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2648723A4 (en) | 2010-12-08 | 2014-04-02 | Univ Vanderbilt | Bicyclic pyrazole compounds as allergic Mglur5 receptor modulators |
| US8865725B2 (en) | 2011-03-15 | 2014-10-21 | Vanderbilt University | Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors |
| WO2012125732A1 (en) * | 2011-03-15 | 2012-09-20 | Vanderbilt University | Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN103910658B (zh) * | 2013-12-23 | 2016-08-17 | 宁夏大学 | 一种硫醚氧化成砜的方法 |
| WO2015165085A1 (en) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2731471A (en) * | 1956-01-17 | Nxg hi | ||
| US2161938A (en) * | 1934-07-31 | 1939-06-13 | Soc Of Chemical Ind | Imidazolines |
| US2457047A (en) * | 1946-02-13 | 1948-12-21 | Monsanto Chemicals | 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same |
| GB725514A (en) | 1952-08-28 | 1955-03-02 | Abbott Lab | Improvements in or relating to 4(5)-aryloxymethylimidazoles and their preparation |
| US2778836A (en) * | 1954-04-02 | 1957-01-22 | Union Chimique Belge Sa | Substituted 2-methyl-delta2 imidazolines |
| US2744910A (en) * | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts |
| US2744909A (en) * | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-phenylbenzyl) imidazoline and acid addition salts |
| US2919274A (en) * | 1957-09-17 | 1959-12-29 | Sahyun Melville | Amidines |
| GB877306A (en) | 1958-04-21 | 1961-09-13 | Pfizer & Co C | Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines |
| DE1121054B (de) * | 1960-11-23 | 1962-01-04 | Merck Ag E | Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen |
| US3202660A (en) | 1961-10-09 | 1965-08-24 | Boehringer Sohn Ingelheim | Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes |
| DE1150180B (de) * | 1962-04-12 | 1963-06-12 | Merck Ag E | Mittel zur Vorbehandlung der Haut fuer die Rasur |
| ES323985A1 (es) | 1966-02-26 | 1966-12-16 | Blade Pique Juan | Procedimiento para la obtenciën de derivados del imidazol |
| US3377247A (en) * | 1967-04-28 | 1968-04-09 | Dow Chemical Co | Antidepressant method |
| US3586695A (en) * | 1968-01-26 | 1971-06-22 | Dow Chemical Co | Substituted imidazolinyl indoles |
| BE754935A (fr) * | 1969-08-13 | 1971-02-17 | Hoechst Ag | 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation |
| US3818094A (en) * | 1969-08-28 | 1974-06-18 | Boehringer Sohn Ingelheim | Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2) |
| US3622579A (en) * | 1969-08-28 | 1971-11-23 | Boehringer Sohn Ingelheim | Derivatives of 2-anilino-1,3-diazacyclopentene-(2) |
| US3660423A (en) * | 1970-02-13 | 1972-05-02 | Dow Chemical Co | 2-(substituted benzyl)methyl-2-imidazolines |
| GB1333471A (en) * | 1971-01-27 | 1973-10-10 | Labaz | Imidazoline derivatives and process for preparing the same |
| JPS49134834A (es) * | 1973-05-07 | 1974-12-25 | ||
| US4125620A (en) * | 1974-10-01 | 1978-11-14 | Boehringer Ingelheim Gmbh | 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof |
| US3992403A (en) * | 1975-05-30 | 1976-11-16 | Schering Corporation | 2-Imidazolines and their use as hypoglycemic agents |
| GB1538097A (en) * | 1976-01-26 | 1979-01-10 | Lafon Labor | Substituted phenyl-amidines |
| US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
| AU518569B2 (en) | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| GB2069481B (en) * | 1980-02-13 | 1983-07-27 | Farmos Oy | Substituted imidazole derivatives |
| GB2092569B (en) * | 1981-02-05 | 1984-09-19 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
| GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| US4540705A (en) | 1983-03-14 | 1985-09-10 | Sterling Drug Inc. | Antidepressant imidazolines and related compounds |
| EP0166937B1 (en) | 1984-06-06 | 1991-08-28 | Abbott Laboratories | Adrenergic compounds |
| US4605661A (en) * | 1984-06-18 | 1986-08-12 | Eli Lilly And Company | Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles |
| LU85747A1 (fr) * | 1985-01-28 | 1986-08-04 | Continental Pharma | Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives |
| US4665095A (en) * | 1985-12-11 | 1987-05-12 | Abbott Laboratories | Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion |
| JPS62265270A (ja) * | 1986-05-13 | 1987-11-18 | Zeria Shinyaku Kogyo Kk | 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤 |
| JPH0774205B2 (ja) * | 1986-12-04 | 1995-08-09 | 三井石油化学工業株式会社 | 新規イミダゾ−ル誘導体 |
| GB2215206B (en) | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| GB2229719B (en) * | 1989-03-30 | 1992-04-29 | Farmos Oy | Novel aromatase inhibiting 4(5)-imidazoles |
| FI894911A0 (fi) | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| FR2669030B1 (fr) * | 1990-11-14 | 1992-12-31 | Adir | Nouveaux derives d'imidazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| CA2211325C (en) | 1993-10-13 | 2006-08-15 | H. Joseph Horacek | Extended release clonidine formulation |
| HUT74386A (en) * | 1993-11-15 | 1996-12-30 | Schering Corp | Phenyl-alkyl imidazoles as h3-receptor antagonists and pharmaceutical compositions containing them |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| US5610174A (en) * | 1995-06-02 | 1997-03-11 | Synaptic Pharmaceutical Corporation | Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US5969137A (en) | 1996-09-19 | 1999-10-19 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| IL123232A0 (en) | 1997-02-11 | 1999-11-30 | Lilly Co Eli | Medicament for inhibiting glucose metabolism deterioration |
| US5866579A (en) * | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
| BR9813381A (pt) | 1997-12-04 | 2000-10-03 | Allergan Sales Inc | "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c" |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| ATE239013T1 (de) | 1997-12-19 | 2003-05-15 | Lilly Co Eli | Hypoglykamische imidazoline derivate |
| AU3534699A (en) * | 1998-04-23 | 1999-11-08 | Takeda Chemical Industries Ltd. | Naphthalene derivatives, their production and use |
| CA2246027A1 (en) | 1998-08-27 | 2000-02-27 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| EP1013243A3 (en) | 1998-12-21 | 2002-10-16 | Benoist Girard Sas | Femoral component for use in replacement hip joint |
| PE20010781A1 (es) | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
| FI20000073A0 (fi) | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | Uusia imidatsolijohdannaisia |
| JP2001302643A (ja) | 2000-04-21 | 2001-10-31 | Suntory Ltd | 環状アミジン化合物 |
| US6495464B1 (en) | 2000-06-30 | 2002-12-17 | Lam Research Corporation | Method and apparatus for fixed abrasive substrate preparation and use in a cluster CMP tool |
| CA2422288A1 (en) | 2000-09-12 | 2002-03-21 | Oregon Health & Science University | Novel mammalian receptor genes and uses |
| EP1339694B1 (en) | 2000-11-14 | 2005-09-21 | F. Hoffmann-La Roche Ag | Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
| IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
| TW200306783A (en) | 2002-04-29 | 2003-12-01 | Fmc Corp | Pesticidal heterocycles |
| KR100492252B1 (ko) | 2002-08-09 | 2005-05-30 | 한국화학연구원 | 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법 |
| WO2006119411A1 (en) | 2005-05-03 | 2006-11-09 | Bayer Cropscience Ag | Insecticidal substituted aminoalkyl heterocyclic and heteroaryl derivatives |
| WO2007024944A1 (en) | 2005-08-25 | 2007-03-01 | Schering Corporation | Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists |
| MX2009004617A (es) | 2006-11-02 | 2009-05-22 | Hoffmann La Roche | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. |
| EP2084152A2 (en) | 2006-11-16 | 2009-08-05 | F. Hoffmann-Roche AG | Substituted 4-imidazoles |
| JP2010513238A (ja) | 2006-12-13 | 2010-04-30 | エフ．ホフマン−ラ ロシュ アーゲー | 微量アミン関連受容体（ｔａａｒ）に対するリガンドとしての新規２−イミダゾール |
-
2007
- 2007-12-05 US US11/950,449 patent/US20080146523A1/en not_active Abandoned
- 2007-12-10 KR KR1020097012493A patent/KR101188992B1/ko not_active Expired - Fee Related
- 2007-12-10 BR BRPI0721291-7A patent/BRPI0721291A2/pt not_active IP Right Cessation
- 2007-12-10 RU RU2009122665/04A patent/RU2465269C2/ru not_active IP Right Cessation
- 2007-12-10 JP JP2009541972A patent/JP5175297B2/ja not_active Expired - Fee Related
- 2007-12-10 WO PCT/EP2007/063585 patent/WO2008074679A2/en not_active Ceased
- 2007-12-10 EP EP07857315A patent/EP2094668A2/en not_active Withdrawn
- 2007-12-10 AU AU2007336351A patent/AU2007336351A1/en not_active Abandoned
- 2007-12-10 CN CN2007800469972A patent/CN101578271B/zh not_active Expired - Fee Related
- 2007-12-10 CA CA002671838A patent/CA2671838A1/en not_active Abandoned
- 2007-12-10 MX MX2009006215A patent/MX2009006215A/es active IP Right Grant
- 2007-12-14 PE PE2007001804A patent/PE20081386A1/es not_active Application Discontinuation
- 2007-12-17 AR ARP070105650A patent/AR064376A1/es unknown
- 2007-12-17 TW TW096148251A patent/TWI345467B/zh not_active IP Right Cessation
- 2007-12-17 CL CL200703653A patent/CL2007003653A1/es unknown
-
2009
- 2009-05-19 NO NO20091936A patent/NO20091936L/no not_active Application Discontinuation
- 2009-05-21 IL IL198878A patent/IL198878A0/en unknown
- 2009-06-02 ZA ZA200903841A patent/ZA200903841B/xx unknown
-
2010
- 2010-04-23 US US12/765,898 patent/US20100204233A1/en not_active Abandoned
-
2011
- 2011-09-19 US US13/235,542 patent/US8399463B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PE20081386A1 (es) | 2008-09-18 |
| WO2008074679A3 (en) | 2008-10-09 |
| CN101578271B (zh) | 2013-06-19 |
| US8399463B2 (en) | 2013-03-19 |
| CN101578271A (zh) | 2009-11-11 |
| KR101188992B1 (ko) | 2012-10-08 |
| US20100204233A1 (en) | 2010-08-12 |
| EP2094668A2 (en) | 2009-09-02 |
| CA2671838A1 (en) | 2008-06-26 |
| TW200833327A (en) | 2008-08-16 |
| RU2009122665A (ru) | 2011-01-27 |
| TWI345467B (en) | 2011-07-21 |
| US20120004230A1 (en) | 2012-01-05 |
| US20080146523A1 (en) | 2008-06-19 |
| AR064376A1 (es) | 2009-04-01 |
| JP2010513373A (ja) | 2010-04-30 |
| WO2008074679A2 (en) | 2008-06-26 |
| IL198878A0 (en) | 2010-02-17 |
| CL2007003653A1 (es) | 2008-07-11 |
| NO20091936L (no) | 2009-07-14 |
| JP5175297B2 (ja) | 2013-04-03 |
| RU2465269C2 (ru) | 2012-10-27 |
| AU2007336351A1 (en) | 2008-06-26 |
| BRPI0721291A2 (pt) | 2014-03-25 |
| ZA200903841B (en) | 2010-03-31 |
| KR20090081431A (ko) | 2009-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006215A (es) | 4-imidazolinas como ligandos de aminas trazas. | |
| SG195156A1 (en) | Pyrazole derivatives | |
| MX2009013742A (es) | 2-imidazolinas. | |
| PH12012500951A1 (en) | Substituted benzamide derivatives | |
| MX2009003887A (es) | Aminometil-2-imidazoles con afinidad con los receptores asociados a trazas de amina. | |
| TW200833685A (en) | Aminomethyl-4-imidazoles | |
| TW200738645A (en) | Use of 4-imidazole derivatives for CNS disorders | |
| PH12013501905A1 (en) | Heterocyclic amine derivatives | |
| UA98951C2 (ru) | 2-аминооксазолины и лекарственное средство, которое их содержит | |
| MX361761B (es) | Derivados de triazol carboxamida. | |
| MX2012005363A (es) | Derivados de oxazolina para el tratamiento de trastornos del sistema nervioso central (snc). | |
| TW200738690A (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
| MA35194B1 (fr) | Derives de benzamide substitues | |
| MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
| MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
| PH12015500489A1 (en) | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinsons disease | |
| MX2009013745A (es) | 4-imidazolinas y su uso como antidepresivos. | |
| MX2009004617A (es) | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. | |
| WO2007090720A3 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
| MX349738B (es) | Derivados de dihidrooxazol-2-amina. | |
| MX2009005047A (es) | 4-imidazoles sustituidos. | |
| NZ744194A (en) | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |